当前位置:首页 - 行情中心 - 金城医药(300233) - 财务分析 - 现金流量表

金城医药

(300233)

  

流通市值:49.25亿  总市值:50.79亿
流通股本:3.72亿   总股本:3.84亿

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金1,147,973,075.64585,641,780.022,345,797,951.181,708,973,946.32
  收到的税费返还2,909,031.11936,341.9510,226,971.337,687,320.75
  收到其他与经营活动有关的现金18,434,520.967,615,216.7166,431,337.3154,969,876.99
  经营活动现金流入小计1,169,316,627.71594,193,338.682,422,456,259.821,771,631,144.06
  购买商品、接受劳务支付的现金406,192,029.73200,902,843.86860,701,758.11650,602,007.59
  支付给职工以及为职工支付的现金299,599,079.3174,769,301.62591,082,789.77463,882,077.55
  支付的各项税费114,441,021.6754,098,500.94205,870,894.6143,315,303.14
  支付其他与经营活动有关的现金155,309,249.6176,920,695.12445,160,776.08329,649,494.21
  经营活动现金流出小计975,541,380.31506,691,341.542,102,816,218.561,587,448,882.49
  经营活动产生的现金流量净额193,775,247.487,501,997.14319,640,041.26184,182,261.57
二、投资活动产生的现金流量:
  取得投资收益收到的现金--1,200,000-
  处置固定资产、无形资产和其他长期资产收回的现金净额40,423,308.2835,276,75023,788,023.27,744,123.2
  收到的其他与投资活动有关的现金1,448,489,360.68563,175,953.611,456,950,656.53742,175,481.7
  投资活动现金流入小计1,488,912,668.96598,452,703.611,481,938,679.73749,919,604.9
  购建固定资产、无形资产和其他长期资产支付的现金41,445,945.5228,113,567.01100,883,345.2974,302,639.62
  支付其他与投资活动有关的现金1,364,100,000662,100,0001,537,011,200813,000,000
  投资活动现金流出小计1,405,545,945.52690,213,567.011,637,894,545.29887,302,639.62
  投资活动产生的现金流量净额83,366,723.44-91,760,863.4-155,955,865.56-137,383,034.72
三、筹资活动产生的现金流量:
  取得借款收到的现金94,000,00060,000,000137,975,000137,975,000
  筹资活动现金流入小计94,000,00060,000,000137,975,000137,975,000
  偿还债务支付的现金137,785,000102,500,000272,030,193.26271,245,193.26
  分配股利、利润或偿付利息支付的现金60,865,813.951,962,169.53162,507,415.06160,296,069.32
  支付其他与筹资活动有关的现金744,240589,0002,136,464.961,425,242
  筹资活动现金流出小计199,395,053.95105,051,169.53436,674,073.28432,966,504.58
  筹资活动产生的现金流量净额-105,395,053.95-45,051,169.53-298,699,073.28-294,991,504.58
四、汇率变动对现金及现金等价物的影响-1,863,133.93-860,202.481,843,586.641,973,205.38
五、现金及现金等价物净增加额169,883,782.96-50,170,238.27-133,171,310.94-246,219,072.35
  加:期初现金及现金等价物余额745,312,799.46745,312,799.46878,484,110.4878,484,110.4
  期末现金及现金等价物余额915,196,582.42695,142,561.19745,312,799.46632,265,038.05
补充资料:
  净利润141,492,562.53-42,273,760.23-
  资产减值准备40,725,721.44-55,662,378.95-
  固定资产和投资性房地产折旧122,388,099.3-249,234,152.58-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧122,388,099.3-249,234,152.58-
  无形资产摊销37,196,284.29-69,760,607.52-
  长期待摊费用摊销1,552,570.92-3,157,542.65-
  处置固定资产、无形资产和其他长期资产的损失-47,831,639.42--2,948,972.26-
  固定资产报废损失366,601.58-1,088,583.68-
  公允价值变动损失117,247.22-86,057.68-
  财务费用10,504,328.25-11,288,052.4-
  投资损失-23,875,917.53--2,787,697.93-
  递延所得税2,012,730.09--2,622,659.53-
  其中:递延所得税资产减少10,192,346.42-16,335,959.18-
    递延所得税负债增加-8,179,616.33--18,958,618.71-
  存货的减少-32,255,172.01-101,367,946.3-
  经营性应收项目的减少6,335,754.06-58,167,638.44-
  经营性应付项目的增加-65,671,750.63--263,480,657.47-
  现金的期末余额915,196,582.42-745,312,799.46-
  减:现金的期初余额745,312,799.46-878,484,110.4-
  现金及现金等价物的净增加额169,883,782.96--133,171,310.94-
公告日期2026-08-212026-04-242026-03-272025-10-27
审计意见(境内)标准无保留意见
TOP↑